Resultados: 2

    Maribavir for treating refractory cytomegalovirus infection after transplant

    Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant. Commercial arrangement There is a simple discount patient access scheme for maribavir. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisat...

    American Society of Transplantation and Cellular Therapy series 4: Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation

    The Practice Guidelines Committee of the American Society of Transplantation and Cellular Therapy (ASTCT) partnered with its Transplant Infectious Disease Special Interest Group (TID-SIG) to update its 2009 compendium-style infectious disease guidelines for hematopoietic cell transplantation (HCT). A new...